Analysis has announced the addition of “Digital Solutions for Biomarkers Market, 2021-2030” report to its list of
Digital solutions for biomarkers are modern solutions
that are capable of generating, collecting, and tracking medical data. From
this data, digital biomarkers that offer insights into anatomical,
physiological, and molecular events, and even behavior-related patterns in
humans, have been acknowledged as viable inputs to understand, track, monitor
and / or predict health-related outcomes. In the current pandemic, medical
professionals are trying to identify digital biomarkers that can facilitate the
successful screening / diagnosis of COVID-19 patients, remotely.
45 digital solutions for biomarkers are currently available / under development
Over 70% of the aforementioned solutions are offered
either as combinations of software applications and devices or as standalone
software solutions, targeting more than 30 unique target indications.
85% of digital solutions for biomarkers are intended for patient monitoring
Such solutions are currently available / being developed
to monitor various digital biomarkers associated with neurological disorders
(22%), respiratory disorders (17%), and infectious disorders (15%). In fact,
over 15% of these solutions are being extensively used for monitoring patients
global events, focused on digital solutions for biomarkers, have been organized
Around 40% of these were conferences, involving more than
25 unique organizers. Close to 50% of such events have been / are being
organized in the US.
USD 950 million invested by both private and public investors in this domain
~70% of the total capital raised by digital solutions for
biomarkers developers was from venture capital funding, featuring the
contributions of over 150 investors. In addition, over 65% was invested in
companies focused on development of physiological / vocal digital biomarkers.
activity in this field has grown at a CAGR of over 60%, between 2016 and 2020
More than 65% of the reported deals were established in
the last two years (since 2019), with the maximum activity being reported in
2020. Majority of the instances captured in the report were research and
development agreements (24%) and product / technology integration agreements
(15%). Further, more than 40% of these agreements have been signed for digital
solutions for physiological biomarkers.
America and Europe are anticipated to capture over 65% of the market share by
The market in Asia-Pacific regions is anticipated to grow
at a relatively faster pace (41.03%). In 2030, digital solutions capturing
vocal biomarkers are likely to represent the largest market share, in terms of
revenues from product sales (37%), followed by those intended to capture
physiological biomarkers (32%) and idiosyncratic biomarkers (16%).
Latest Market Insights: Digital Biomarkers Market is projected to be worth over USD 22 billion by 2030
Who are the leading players engaged in the
development of digital solutions for biomarkers?
Which are the popular therapeutic areas where
digital biomarkers are currently relevant?
What kind of global level events related to
digital biomarkers, have been organized in the recent past?
What is the trend of capital investments in
the digital biomarkers market?
Which partnership models are most commonly
adopted by stakeholders in this industry?
What is the tole of big pharma players
engaged in this domain?
How has the COVID-19 pandemic impacted the
digital biomarkers market?
What are the opportunities available for
digital solutions for biomarkers in emerging markets?
How is the current and future opportunity
likely to be distributed across key market segments?
What are the anticipated future trends
related to digital solutions for biomarkers market?
USD 22.6 billion (by 2030) financial opportunity within the digital solutions
for biomarkers market has been analyzed across the following segments:
Software Application + AI Support
Software Application + Device
Standalone Software Application
Other Contents of Solutions
Mental Health Problems
Substance Use Disorders
Business to Business (Healthcare Providers,
Payers, Employers and Pharmaceutical Companies)
Business to Consumer (Patients and Caregivers)
Middle East and North Africa
Rest of the World
report features inputs from eminent industry stakeholders, according to whom,
digital biomarkers are soon likely to witness increased adoption given their
broad scope of applications and the availability of technologies that enable
such biological inputs to be remotely identified and processed. The report
includes detailed transcripts of the discussions held with following industry experts:
Edouard Gasser (Co-Founder and Chief
Executive Officer, Tilak Healthcare)
Michael Seggev (Chief Commercial Officer,
research covers brief profiles of key players engaged in the development of
digital solutions for biomarkers; other popular industry players featured in
the report include:
for Customization: Request Sample - Digital Solutions for Biomarkers Market, 2021-2030 | Industry Analysis | Market Size | 2030
Analysis is one of the fastest growing market
research companies, sharing fresh and independent perspectives in the
bio-pharmaceutical industry. The in-depth research, analysis and insights are
driven by an experienced leadership team which has gained many years of
significant experience in this sector. If you’d like help with your growing
business needs, get in touch at [email protected]
Analysis Private Limited
(415) 800 3415
Visit Our Latest Publication:
Cloud-based Solutions for Drug Discovery,
Development and Manufacturing Market Size by 2030
CAR-T Cell Therapies Market 2030
Patient Recruitment and Retention Services
mRNA Therapeutics and Vaccines Market Growth By 2030
T-Cell (CAR-T, TCR, and TIL) Therapies
Analysis and Forecast by 2030